Roche’s RG6206 becomes second myostatin inhibitor to fail in DMD in past year

The failure of Roche’s RG6206 marks another blow to the hypothesis that blocking myostatin can improve muscle growth and function in ambulatory boys with Duchenne muscular dystrophy.

Roche (SIX:ROG; OTCQX:RHHBY) sent a letter Wednesday to the DMD community, including non-profit Parent Project Muscular Dystrophy (PPMD), disclosing that the company was discontinuing development of the anti-MSTN adnectin IgG1-Fc fusion protein after a preplanned interim futility analysis showed RG6206 was unlikely to meet the primary endpoint of an improvement in the North Star Ambulatory Assessment in the Phase II/III SPITFIRE trial...